







Anti-dementia medications –                                 
fighting a losing battle? 
 
Ana Micov*, Uroš Pecikoza  
 
University of Belgrade – Faculty of Pharmacy, Department of Pharmacology,              
Vojvode Stepe 450, 11221 Belgrade, Serbia 
 
*Corresponding author:  Ana Micov, PhD 
    e-mail: anamicov@pharmacy.bg.ac.rs 
 
Summary 
Alzheimer’s disease (AD), the most common cause of dementia, is growing health, social 
and economic issue because of the increasing number of sufferers, limited efficacy of available 
treatment options, and high total healthcare costs. It is clinically characterized by cognitive and 
behavioral impairments, both of which need to be treated appropriately to improve patients’ 
quality of life and their caregivers as well. Currently, available anti-dementia medications 
provide only modest and transient cognitive benefits. Donepezil, rivastigmine and galantamine 
(cholinesterase inhibitors) are indicated for the symptomatic management of mild to moderately 
severe AD, while memantine (NMDA glutamate receptors antagonist) is recommended for 
moderate-to-severe AD. A special focus on behavioral symptoms (e.g. anxiety, depression, 
aggression) management is required as they cause great suffering in patients/caregivers. The use 
of medications that can impair cognitive function, such as drugs with anticholinergic activity, 
should be avoided in patients with dementia. Additionally, interventions that could delay or 
prevent dementia onset in some subjects are focused on minimizing modifiable risk factors 
(hypertension, diabetes, depression) and maximizing protective factors (physical activity, 
healthy diet, leisure, and social activities). The treatment of AD remains a challenge. 
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Introduction   
To fight a losing battle is not a promising beginning, but it aims to draw attention 
to one of the biggest challenges facing modern medicine, that is the increasing number 
of dementia sufferers on the one hand, and very limited therapeutic options on the other 
(1,2). Thus, raising dementia awareness and implementing measures for its 
prevention/treatment are within the scope of practice of all healthcare professionals. 
 It is very important to make a difference between key terms that partially overlap 
and are misused as synonyms. Dementia is a clinical syndrome characterized by 
progressive loss of cognitive abilities that significantly impairs the performance of daily 
living. While memory impairment is the most common in dementia patients, other 
cognitive domains such as language, visuospatial ability, and executive functions are 
also affected. Behavioral disorders such as depression, hallucinations, delusions and 
agitation, also develop in many dementia syndromes. Symptoms of dementia usually 
develop gradually and tend to get worse over time. It is estimated that dementia 
develops in 6-10% of the population aged 65 and above, so an increasing number of 
sufferers and costs worldwide are driven by increased longevity (2-4). Alzheimer’s 
disease is the most common cause of dementia (60-70%), followed by vascular, Lewy 
bodies, and frontotemporal dementias. Mixed dementias in which more than one type of 
dementia occur simultaneously are also common (3,4). The crucial issue in all dementia 
syndromes is that cognitive impairments are sufficiently pronounced to disrupt daily 
living activities and social functioning. Mild cognitive impairment is an acquired 
cognitive deficit without significant impairment of daily living activities (3,4). Nearly 
half of people with this cognitive impairment will progress to dementia, usually of 
Alzheimer’s type, in 3 years. It is still unknown why some subjects develop dementia 
and others do not (2,4). 
Altogether, dementia syndromes (especially Alzheimer’s disease) are highly 
prevalent conditions, adversely affect patient quality of life, burden caregivers, increase 
institutionalization, and are costly to families and society. Additionally, there are 
stigmatising beliefs attached to dementia, which can cause people to avoid diagnosis. 
Therefore, in this work available and potentially novel treatment options for 
Alzheimer’s disease will be discussed. 
Alzheimer’s disease 
Alzheimer’s disease (AD), the most common dementia type, is a progressive, 
irreversible neurodegenerative disease followed by a mental decline of patients. The 
prevalence of AD is rising and reaching epidemic proportions (5,6). Usually, 
symptomatic AD lasts about 8-10 years. Some patients with AD show a steady decline 
in cognitive functioning while others have extended plateaus with no significant clinical 




toll for family members and caregivers is immeasurable (4,8). According to the World 
Health Organization, AD and other dementias are the fifth global cause of death (9). 
Thus, AD is a growing health, social, and economic problem. 
Risk factors for AD development can be classified as unmodifiable (age, 
genotype, female sex) and potentially modifiable (vascular risk factors, depression, 
hearing loss, head injury, lack of physical activity, environmental factors), either by 
pharmacological measures or lifestyle modification. The single most important risk 
factor for AD is increasing age (> 65 years). In this regard, it needs to be emphasized 
that AD and other dementias are not a part of normal aging. A positive family history of 
dementia implies a genetic contribution to AD, but autosomal dominant inheritance 
occurs only in 2,5-5% of patients. Female sex is another unmodifiable risk factor that is 
not related to the general greater longevity of women (3,4). It is estimated that about a 
third of AD cases worldwide could be attributed to potentially modifiable risk factors 
(9), but no convincing data on beneficial effects of risk factors control have been 
reported in clinical settings (2,3,11). However, interventions to minimize risk factors 
and maximize protective factors may be considered justified in light of their overall 
health benefits (2,3,11). Interventions to minimize risk factors for AD include 
appropriate management of vascular risk factors (hypertension, diabetes, insulin 
resistance, and dyslipidemia - especially in midlife age) and depression, smoking 
cessation, caution with exposure to proposed environmental risk factors (aluminium, 
mercury, and viruses) (2,3,7). On the other side, certain lifestyle habits are linked to 
lower risk for AD and are recognized as protective factors. These include a higher level 
of education (formation of „cognitive reserve”), physical activity (positive effects on 
plasticity and cerebral circulation), Mediterranean-like diet (antioxidant and anti-
inflammatory properties), leisure (reading, playing board games/musical instruments, 
dancing – serve as cognitive training) and social activities (1-3, 12-14). 
Drug-induced dementia symptoms 
„Any new symptom in an older patient should be considered a possible drug side 
effect until proved otherwise”.  
This frolicsome statement seems to be appropriate in the case of AD, as many 
commonly used medications may cause undesirable effects that mimic dementia 
symptoms, especially in older adults. As AD is associated with a deficiency in brain 
acetylcholine levels, centrally acting anticholinergic medications particularly negatively 
impact cognition. First-generation antihistamines (e.g. diphenhydramine, 
dimenhydrinate, promethazine), tricyclic antidepressants (e.g. amitriptyline, doxepin, 
imipramine), and bladder antimuscarinics (e.g. oxybutynin, tolterodine) are the most 
commonly prescribed anticholinergic drugs and should be ruled out first when drug-




olanzapine, clozapine) and antiparkinsonian drugs                     (e.g. trihexyphenidyl, 
biperiden) with anticholinergic properties are also often used (15,16). Some over-the-
counter (OTC) medications (e.g. dimenhydrinate, diphenhydramine; regimens vary by 
country) used in self-medication to treat colds and allergies, as well as sleep aids, are 
linked to cognitive impairment in older adults. Anticholinergic drugs-induced cognitive 
impairment is considered to be reversible upon medication discontinuation, but there is 
also evidence that anticholinergic treatment may be associated with a higher risk of 
dementia development. Nonetheless, some drugs without anticholinergic potentials, 
such as benzodiazepines, non-benzodiazepine sedative-hypnotics, and anticonvulsant 
drugs, have also been associated with cognitive and/or behavioral impairment (15,16). 
Therefore, the use of drugs that could negatively impact cognition should be limited or 
discontinued (if possible) in subjects with high risk for dementia, and dementia patients 
as well.   
Rationale for the pharmacological treatment of Alzheimer’s disease 
Compelling data support the amyloid cascade hypothesis in the pathogenesis of 
AD, by which slow and progressive accumulation of aggregates of the toxic β-amyloid 
peptide (Aβ) in the brain triggers a complex pathological cascade leading to 
neurodegeneration and dementia symptoms (17). Aβ production depends on the 
proteolytic processing of the amyloid precursor protein (APP) by enzymes β- and γ-
secretases. Aβ exists in various lengths, including the non-toxic Aβ40 and the toxic 
Aβ42 forms. Non-toxic Aβ and APP probably have a protective role, while Aβ42 
aggregates form oligomers, fibrils, and ultimately insoluble extraneuronal amyloid 
plaques (a neuropathological hallmark of AD). Aβ42 oligomers promote 
hyperphosphorylation of the tau protein and its deposition into neurofibrillary tangles 
intracellularly (a neuropathological hallmark of AD). There is a strong correlation 
between tau pathology and neuronal loss and consequently disease severity (17,18).  
In a functional sense, the amyloid cascade causes synaptic dysfunction, neuronal 
dysfunction, and loss, primarily in the neocortex, associative regions of the 
hippocampus, amygdala complex, and nucleus basalis Meynert (NBM), i.e. in brain 
structures that are important for cognition. The NBM is the major source of cholinergic 
innervation of the cerebral neocortex. Degeneration of these neurons results in a 
decreased acetylcholine level, which correlates with the severity of the cognitive deficit. 
Disorders in glutamatergic, serotonergic, and noradrenergic transmission also occur 
(7,17).  
Thus, the amyloid hypothesis provides the rationale for therapeutics designed to 
(5,18): 
 target production/accumulation of toxic Aβ peptides, Aβ aggregates (especially 




excretion and/or intracellular signaling cascades leading to nerve degeneration 
=> potential disease-modifying based therapy 
 target levels of neurotransmitters (to increase 
cholinergic/noradrenergic/serotonergic and decrease glutamatergic 
transmission) => symptomatic based therapy.  
Pharmacological treatment for Alzheimer’s disease 
The treatment of AD is still a great challenge. Currently, available medicines for 
AD cannot slow down or stop disease progression but can ease symptoms for a while 
and improve life quality for both patients and their carers. As AD progresses, neurons 
die and cell connections are lost, causing worsening of cognitive symptoms. Thus, 
treatment should be initiated without delay. Dementia treatment could address problems 
with cognition and behavior as well (1,3,19). Thus, we will discuss the management of 
cognitive and behavioral symptoms associated with AD. 
Management of cognitive symptoms 
Currently available drugs, cholinesterase inhibitors and memantine, provide only 
modest and transient cognitive benefits. Therefore, it is important to have realistic 
expectations regarding therapy, especially by the patient’s family and caregiver(s). 
Donepezil, rivastigmine and galantamine 
Cholinesterase inhibitors (ChEI), donepezil, rivastigmine, and galantamine, are 
indicated for the symptomatic management of mild to moderately severe AD (20,21). 
Rivastigmine is also licenced for the treatment of mild to moderately severe dementia 
associated with idiopathic Parkinson's disease (20,21). ChEIs appear beneficial for 
dementia with Lewy bodies, which may be considered an „off-label” indication (19).  
Clinical efficacy. Cognitive and overall benefits of ChEIs, although modest, have 
been confirmed in numerous clinical studies in patients with mild to moderate AD 
(1,22). Some reputable sources state that ChEI (particularly donepezil) could also help 
people in the later stages of AD, so physicians may continue to prescribe one of these 
drugs for longer if they realize it is still having a beneficial effect (23,24). From the 
patients' perspective, about 40–70% of those taking a ChEI find it helps them (6). So 
far, no difference in the effectiveness between ChEIs has been shown, but some people 
may respond more favorably to one ChEI than another. Some guidelines (e.g. NICE 
guidance) suggest that the cheapest drug (currently donepezil) should generally be tried 
first (6,19). If no response is achieved with one of the ChEIs, it should be replaced by 
another, and if that attempt does not lead to results, a third ChEI should not be tried. 
After 6 to 12 months (possibly longer with donepezil) the beneficial effect of ChEIs on 




the patient is still taking medications. Therefore, as the disease progresses, therapy will 
need to be re-evaluated (1,3,7). Discontinuation of ChEI treatment can lead to the loss 
of beneficial cognitive and functional effects that may not have been evident. Because 
limited data on their long-term biological and clinical effects are available, there is no 
clear consensus of how long ChEIs should be prescribed. Therefore, the decision about 
whether to continue therapy should be individualized. If a patient is still having 
beneficial effects to ChEI therapy, treatment is generally continued as long as the 
patient/his caregiver is willing to continue with the medication, remains reasonably 
adherent, and does not have intolerable adverse drug effects. The treatment goals should 
be agreed upon with the patient (his caregiver), with monitoring of the patient over 
time, for both drug-related beneficial and adverse effects (6,25).     
Mechanism of action. Donepezil, rivastigmine, and galantamine work in a similar 
way by preventing the enzyme acetylcholinesterase from breaking down acetylcholine. 
As stated previously, decreased cortical acetylcholine levels in dementia patients are in 
correlation with an increase in cognitive symptoms. Accordingly, ChEIs by increasing 
the amount of acetylcholine and most likely activating muscarinic M1 receptors (play  a  
crucial  role  in  cognitive  functions  like  learning  and memory), improve the 
communication between nerve cells in cholinergic synapses and consequently diminish 
cognitive impairment (3,7,17,26). The dosing and titration schedule of the ChEIs is 
presented in Table 1. 
Undesirable effects. Most patients tolerate ChEIs well. The most common side 
effects of donepezil, rivastigmine, and galantamine are diarrhoea, muscle cramps, 
fatigue, nausea, and vomiting. Side effects are less likely to occur when treatment is 
started with lower doses (1,20,21). Some patients taking donepezil complain of vivid 
dreams and nightmares and in these cases morning dosing may be preferred. There is an 
evidence that patients who do not tolerate one ChEI may tolerate another, so changing 















Table I  Pharmacological management of cognitive symptoms of Alzheimer’s disease   
 (20,21) 




















• oral dispersible tablets 
(5 and 10 mg) 
• treatment is started with           
5 mg/day (once-a-day 
dosing) 
• following a one-month 
clinical assessment of 
treatment at  5 mg/day, the 
dose can be increased to      
10 mg/day (maximum 
recommended daily dose) 
• donepezil is 
taken usually at 









(1.5, 3, 4.5 and 6 mg) 
 




oral dosage forms 
• treatment is started with      
1.5 mg twice a day 
• if well tolerated; after a 
minimum of two weeks, the 
dose should be increased to      
3 mg twice a day, and 
subsequently up to 6 mg 
twice a day (maximum 
recommended daily dose) 
transdermal patches 
• treatment is started with          
4.6 mg/24 h 
• if well tolerated, after a 
minimum of four weeks, the 
dose should be increased to      
9.5 mg/24 h, the daily 
recommended effective dose 
• patches may be 
better for people 
who can not take 
medication by 
mouth 
• only one patch 
should be used at 
any one time 
• new patch should 
be put on a 
different area of 
the skin, to avoid 
a rash 
Galantamine Alzamin® • prolonged release 
capsules 
  (8, 16 and 24 mg) 
• treatment is started with          
8 mg/day for four weeks, 
increasing to 16 mg/day for 
another four weeks, and then 
kept at a dose between        
16 mg and 24 mg daily 
(maximum recommended 
daily dose) 
• galantamine is 
taken once a day 
in the morning, 
preferably with 
food 
• capsules must 






   (10 and 20 mg) 
• treatment is started with          
5 mg/day, increasing the 
dose every week by 5 mg, up 
to 20 mg/day after four 
weeks (recommended 
maintenance dose is                
20 mg/day) 
• memantine is 
usually given in 








Memantine is approved for the treatment of moderate to severe AD (20,21). 
Memantine monotherapy could be recommended as an option for patients with 
moderate AD who do not tolerate or have a contraindication to ChEIs (19). It could be 
also offered to people with Lewy body dementia if ChEIs are not tolerated or are 
contraindicated (19). Research is underway to learn more about whether memantine 
might be beneficial for people with other forms of dementia. 
Clinical efficacy. Like ChEIs, memantine represents symptomatic therapy of AD. 
Memantine can improve cognitive symptoms, but there is an evidence that it may also 
help with behavioral symptoms such as delusions, aggression, and agitation (1). There is 
an important difference in the efficacy of memantine depending on the stage of the 
disease. The notable clinical benefit of memantine in patients with moderate-to-severe 
AD was observed, while patients with mild AD have no beneficial effect (27). A 
consensus has been reached that memantine and ChEIs combination in patients with 
moderate-to-severe AD shows small but significant improvement of overall functioning, 
cognitive and behavioral symptoms with acceptable tolerance, in comparison to ChEIs 
alone (28). This observation is pharmacologically expected because these drugs have 
complementary mechanisms of action. 
Mechanism of action. Memantine blocks NMDA glutamate receptors thereby 
interrupting excessive glutamatergic activity. Excessive glutamate production, which 
results in the excessive flow of calcium into neurons through NMDA receptors, plays an 
important role in the pathogenesis of AD (17,27). Thus, the clinical actions of 
memantine are likely to be associated with a decrease in this excitotoxicity (27). 
Undesirable effects. The most frequently occurring adverse reactions to 
memantine are dizziness, headaches, constipation, somnolence, and hypertension. These 
effects are usually only temporary. Concomitant use of memantine and amantadine 
(chemically related NMDA-antagonist), L-dopa or dopamine receptor agonists (e.g. 
pramipexole, ropinirole) may result in clinically relevant interactions due to an 
increased risk of CNS toxicity. Thus, caution or avoidance (in the case of amantadine) 
is needed with mentioned comedications (1,20,21).  
Many other treatments, such as cerebrolysin, nicergoline, piracetam, 
pentoxyfylline, selegiline, and vinpocetine are used in some countries as treatments for 
AD. There are no convincing data for the efficacy of these drugs in AD management 





Management of behavioral symptoms 
Behavioral symptoms, such as anxiety, depression, aggression, paranoia, sleep, 
and appetite disorders, are very common (occur in 80-90% of patients) in AD. These 
symptoms cause much suffering to patients and their carers, sometimes more than 
cognitive impairment. Clinical evidence indicates a high placebo response, thus safe 
nonpharmacological measures should be, wherever possible, firstly tried as some 
symptoms may resolve over time. Pharmacotherapy should be reserved for more severe 
cases, as it is often associated with unfavorable outcomes. Selective serotonin reuptake 
inhibitors and trazodone may be useful for anxiety and depression treatment in dementia 
because they are devoid of anticholinergic properties. Antipsychotics, conventional and 
atypical, may reduce agitation, paranoid and aggressive behavior, but may also increase 
the risk for fatal outcomes due to stroke and cardiovascular events, and the risk of 
infections such as pneumonia. Therefore, antipsychotics should be used with caution 
after careful assessment of risk and benefit. Anticonvulsives, carbamazepine or 
oxcarbazepine, are considered helpful for agitation/aggression („off-label” use), and 
may be used in combination with atypical antipsychotics as needed (1,7,29). 
(Lack of) Efficacy of pharmacological treatments in the prevention of 
Alzheimer’s disease 
Several pharmacological treatments have been tested to reduce the risk of AD 
development. It was found that vitamin supplementation (B, E, or multi-complex), 
nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, statins, menopause hormone 
therapy (estrogen and estrogen-progestin) do not reduce the risk of subsequent AD 
development in cognitively normal subjects and should not be recommended. No 
treatment (cholinesterase inhibitors, vitamin E, NSAIDs, aspirin, statins, menopause 
hormone therapy) has been shown to be effective in preventing/delaying the 
development of AD in subjects with mild cognitive impairment and should not be 
recommended (1,3,11).  
The inconsistent pattern of benefit associated with Ginkgo biloba was observed in 
subjects having normal basal cognition or mild cognitive impairment. Further evidence 
is needed to clearly establish the efficacy of Gingko (1,2). 
Research into new treatments 
 „Nihil novum sub sole” 
Although great strides have been made in understanding AD pathophysiology, 
there are no approved disease-modifying medications for AD and no new drugs have 
been licensed for the management of cognitive symptoms since memantine in 2002 (in 




When it comes to disease-modifying therapy, the majority of drugs tested in the 
past 15 years have targeted the accumulation and deposition of the Aβ peptide. Despite 
the evident Aβ clearance and/or attenuation of neuropathological changes in certain 
brain regions, anti-amyloid drugs tested so far failed to provide meaningful clinical 
benefits in patients with prodromal, mild, and moderate AD (18,30). Unexpectedly, 
some drugs such as verubecestat, a β-secretase inhibitor, were found to worsen 
cognition (31), while Aβ immunotherapy (i.e. vaccination with Aβ oligomers, which 
induces an immune response against Aβ oligomer aggregation and promotes its 
clearance) caused meningoencephalitis (32). These disappointing results have raised the 
possibility that Aβ is a byproduct of the AD pathology, rather than its cause, casting 
doubt on the prevailing amyloid hypothesis of AD. To overcome this problem, research 
efforts are currently focused on the most neurotoxic species, Aβ oligomers, and 
monoclonal antibodies directed against these oligomers such as aducanumab, 
solanezumab which are (were) in phase 3 clinical trials (30). Further, drugs are now 
being tested in asymptomatic stage of AD (i.e. in cognitively intact subjects at risk of 
AD), having in mind that Aβ accumulation in the brain starts 15–20 years before the 
clinical onset of dementia (5,30). Approaches directed against tau aggregation, CNS 
inflammation, and brain insulin resistance, are also in the focus of ongoing clinical 
studies (18). 
Something very unusual happened recently. The company that developed 
aducanumab announced that this anti-amyloid antibody failed futility analyses in phase 
3 clinical trials in patients with prodromal or mild AD, and discontinued the study and 
further drug development (March 2019). A little bit later (October 2019), the same 
company disclosed that they were applying for US Food and Drug Administration 
(FDA) marketing approval of aducanumab. After they reanalyzed the data it was found 
that aducanumab given at high doses actually reduced clinical decline in patients with 
early AD (33). We will find out soon if the first disease-modifying therapy will be 
approved. 
Role of the pharmacist in dementia treatment 
Pharmacists could certainly play a more important role in the care of patients with 
dementia than they currently have. Due to their accessibility and expertise in the 
appropriate utilization of prescription and OTC medications, and dietary supplements as 
well, pharmacists are uniquely positioned to help dementia patients at all stages of the 
disease (asymptomatic, prodromal, and symptomatic). As dementia occurs in older 
people, when comorbidity and comedication are common, pharmacists by having access 
to patient medications list, can timely recognize the adverse impact of concomitant 




Community pharmacist-led interventions in prevention/treatment of AD could 
include (34-36): 
 identifying subjects with risk factors for AD => suggest healthy lifestyle habits 
 identifying subjects with early symptoms of cognitive decline associated with 
AD (subtle short-term memory changes, difficulty finding the right words and 
completing normal tasks, mood changes, disorientation in time or space, 
misplacing items, being repetitive) => refer subjects with suspected dementia 
symptoms to physicians  for follow up 
 screening patients’ medication list for drugs that could impair cognition, 
especially with the increased anticholinergic burden (including those available 
as OTC medicines) => consider minimizing the use of such medicines, and, if 
possible, look for alternatives in consultation with prescribers 
 educating and counseling patients and their caregivers about the disease course, 
the efficacy and safety of available treatment options to improve treatment 
adherence and maintain patients’ independence 
 therapy monitoring to determine problems such as medication failure, non-
adherence, and side effects => continue with counseling and look for 
interventions that may overcome the problem (alternative 
medication/formulation/delivery method/regimen) in consultation with 
prescribers. 
Conclusion 
Let us hope we have not lost the battle with dementia yet. It is probably more 
prudent and rational not to fight the battle, but to adopt healthy lifestyle habits from 
early life and to control modifiable risk factors, as the current treatment options provide 
only modest clinical benefit and novel treatments are still uncertain. The role of 
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Alzheimer-ova bolest (AB), najčešći oblik demencije, rastući je zdravstveni, socijalni i 
ekonomski problem zbog sve većeg broja obolelih, nedovoljne efikasnosti postojećih terapijskih 
mera, kao i velikih ukupnih troškova nege. Klinički se manifestuje smanjenjem kognitivnih 
funkcija i poremećajima ponašanja, koje treba adekvatno lečiti kako bi se popravio kvalitet 
života obolelih i njihovih negovatelja. Raspoloživi lekovi za lečenje demencija ostvaruju 
umereno i prolazno poboljšanje kognitivnih funkcija. Donepezil, rivastigmin i galantamin 
(inhibitori holinesteraza) su indikovani kao simptomatska terapija blage do umereno teške 
forme AB, dok se memantin (antagonist glutamatergičkih NMDA receptora) preporučuje za 
lečenje umerene do teške AB. Poseban aspekt lečenja predstavlja terapija bihejvioralnih 
simptoma (anksioznost, depresija, agresivnost), koji su veliki problem za pacijente i 
negovatelje. Trebalo bi izbegavati primenu lekova koji nepovoljno utiču na kogniciju, kao što su 
lekovi sa antiholinegičkim dejstvom, kod pacijenata sa demencijom. Dodatno, kontrola 
promenljivih faktora rizika (hipertenzija, dijabetes, depresija) i usvajanje protektivnih faktora 
(fizička aktivnost, zdrava ishrana, socijalne aktivnosti i aktivnosti u slobodno vreme) možda 
može da spreči ili odloži pojavu demencije kod izvesnih ljudi. Lečenje AB i dalje je veliki 
izazov. 
 
Ključne reči:  Alzheimer-оvа bolest, donepezil, rivastigmin, galantamin, memantin,  
  uloga farmaceuta 
 
 
